Discover the Roche data presentations at ASH 2021.

With 50 abstracts accepted at ASH this year, we have made it easier for you to navigate the directory with our featured abstracts by disease area. 

Therapy
Area
Full title Abstract
number
Session
type
Link to Presentation/Poster
AML Cost-Effectiveness Analysis of Venetoclax Plus Azacitidine vs. Azacitidine in Newly Diagnosed Adult Patients With Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy From a United States Payer Perspective 112 Oral Link to Presentation/Poster
AML Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States 2290 Poster Link to Presentation/Poster
AML Outcomes in Patients with Poor-risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents 224 Oral Link to Presentation/Poster
AML Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 Mutation in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia 691 Oral Link to Presentation/Poster
AML Comparative Effectiveness of Venetoclax Combinations vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative 2328 Poster Link to Presentation/Poster
AML Real-World Management of Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax-based Regimens: Results from the AML Real World Evidence (ARC) Initiative 1271 Poster Link to Presentation/Poster
CLL Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 MURANO Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx) 1548 Poster Link to Presentation/Poster
CLL Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in The United States (US) 4086 Poster Link to Presentation/Poster
CLL ReVenG: A Phase 2 Study of Venetoclax plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia 2634 Poster Link to Presentation/Poster
CLL Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate is Slower Following Venetoclax-Rituximab (VenR): Results From a Minimal Residual Disease (MRD) Model From the Randomized Phase 3 MURANO Trial 1551 Poster Link to Presentation/Poster
DLBCL The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma LBA-1 Oral Link to Presentation/Poster
DLBCL Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) 525 Oral Link to Presentation/Poster
DLBCL Cost of Disease Progression After Frontline (1L) R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL) 3002 Poster Link to Presentation/Poster
DLBCL Exploring the Impact of Aggressive Diffuse Large B-cell Lymphoma (International Prognostic Index [IPI] 2-5) on Clinical and Patient-relevant Outcomes in the Context of a Clinical Trial 3577 Poster Link to Presentation/Poster
DLBCL POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 3568 Poster Link to Presentation/Poster
FL Obinutuzumab Short Duration Infusion is Preferred by Healthcare Providers and has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma 1345 Poster Link to Presentation/Poster
FL Healthcare Resource Utilization and Costs Associated with Obinutuzumab plus Bendamustine versus Rituximab plus Bendamustine for First-Line Treatment of Follicular Lymphoma 3004 Poster Link to Presentation/Poster
FL Glofitamab as Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL) 128 Oral Link to Presentation/Poster
FL Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: pivotal results from a Phase I/II study 127 Oral Link to Presentation/Poster
FL Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed/refractory follicular lymphoma: initial results from a Phase Ib study 129 Oral Link to Presentation/Poster
FL Treatment Patterns and Outcomes in patients with Relapsed/Refractory Follicular Lymphoma who received Third line Therapy at the Christie NHS Foundation Trust in the UK 5011 Publication only  
FL Healthcare Resource Utilization and Costs of Patients with Relapsed/Refractory Follicular Lymphoma Receiving 3 or More Lines of Therapy 1923 Poster Link to Presentation/Poster
FL Treatment Patterns and Outcomes Among Patients with Relapsed/Refractory Follicular Lymphoma Treated in Routine Clinical Practice in the US with Three or More Lines of Therapy 4080 Poster Link to Presentation/Poster
Hemophilia A Improvement in Annualized Bleed Rate in Patients with Hemophilia A Initiating Emicizumab – Physician Reported Outcomes from the Adelphi Hemophilia A Disease Specific Programme 1961 Poster Link to Presentation/Poster
Hemophilia A Characterizing Mild and Moderate Hemophilia A Patients in the Real World: A Patient-Centric Approach 2107 Poster Link to Presentation/Poster
Hemophilia A Evaluation of the Safety of Emicizumab Prophylaxis in Persons with Hemophilia A: An Updated Summary of Thrombotic Events and Thrombotic Microangiopathies 3186 Poster Link to Presentation/Poster
Hemophilia A A Novel Methodology for Building Longitudinal, Patient-Centric Real World Datasets in Hemophilia A 594 Oral Link to Presentation/Poster
Hemophilia A Emicizumab Prophylaxis in Persons with Hemophilia A, Aged ≥50 Years, with Comorbidities – Pooled Data from Four Phase III Studies (HAVEN 1, 3, and 4, and STASEY) 2103 Poster Link to Presentation/Poster
Hemophilia A Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study 343 Oral Link to Presentation/Poster
Hemophilia A Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry 347 Oral Link to Presentation/Poster
Hemophilia A Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis 344 Oral Link to Presentation/Poster
MCL Glofitamab Step-Up Dosing Induces High Response Rates in Patients (pts) With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), most of whom had failed prior Bruton’s tyrosine kinase inhibitor (BTKi) therapy 130 Oral Link to Presentation/Poster
MDS Molecular Responses are Observed Across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax plus Azacitidine 241 Oral Link to Presentation/Poster
MDS Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome 537 Oral Link to Presentation/Poster
MM Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing Phase I study 157 Oral Link to Presentation/Poster
MM Assessment of Associations between Derived Response and Overall Survival in Patients with Multiple Myeloma using a US-Based Electronic Health Records Database 3770 Poster Link to Presentation/Poster
MM Lab-based Response Assessment Algorithm Recapitulates Investigator’s Response Assessment in the Phase 3 Bellini Trial 4758 Publication only  
MM Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma 84 Oral Link to Presentation/Poster
MM A Phase I Study of RO7297089, a B Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) 2755 Poster Link to Presentation/Poster
NHL Glofitamab Monotherapy Provides Durable Responses After Fixed-Length Dosing in Relapsed/Refractory (R/R) non-Hodgkin Lymphoma (NHL) Patients (pts) 2478 Poster Link to Presentation/Poster
NHL Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy 1459 Poster Link to Presentation/Poster
NHL Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 step-up dosing is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study 3573 Poster Link to Presentation/Poster
NHL Mosunetuzumab plus polatuzumab vedotin has promising efficacy and a favorable safety profile in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: updated results from a Phase Ib/II study 533 Oral Link to Presentation/Poster
NHL, DLBCL Glofitamab Plus R-CHOP Induces High Response Rates With Minimal Cytokine Release Syndrome (CRS) in Patients (pts) with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and Previously Untreated (1L) Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results From a Dose-Escalation and Safety Run-in Phase Ib Study 2479 Poster Link to Presentation/Poster
PNH Clinical Profile and Long-term Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab in a Real-World Setting: High Frequency of Anemia Despite Decreased Intravascular Hemolysis 4314 Publication only  
PNH Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab vs Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti–Complement Therapy 4313 Publication only  
SCD Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase Ib CROSSWALK-a Trial Evaluating the Safety of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD) 3108 Poster Link to Presentation/Poster
SCD Trial in Progress: The Randomized, Double-Blind, Placebo-Controlled Phase IIa CROSSWALK-c Trial Evaluating the Efficacy of Crovalimab as Adjunct Treatment in the Prevention of Vaso-Occlusive Episodes (VOEs) in Patients with Sickle Cell Disease (SCD) 3111 Poster Link to Presentation/Poster

No filter results

Venetoclax is being developed by AbbVie and Roche. It is jointly commercialised by AbbVie and Genentech, a member of the Roche group, in the US and commercialised by AbbVie outside of the US. All information requests outside of the US must be sent directly by the requesting physician or other HCP to AbbVie using the mailbox: gmi@abbvie.com


Polatuzumab vedotin is being developed by Roche in collaboration with SeaGen